カーウェオール
Based on 1 publication(s) in Google Scholar
Kahweol is one of the consituents of the coffee from Coffea Arabica with anti-inflammatory anti-angiogenic, and anti-cancerous activities. Kahweol inhibits adipogenesis and increase glucose uptake by AMP-activated protein kinase (AMPK) activation. Kahweol induces apoptosis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.0%
- CAS 番号: 6894-43-5
- 分子式: C20H26O3
- 分子量:314.42
-
保管条件:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Kahweol
MoreAMPK アイソフォーム固有の製品をすべて表示
More
生物活性
AMPK; adipogenesis; apoptosis[1]
Kahweol (20-40 μM; 24 hours) decreases TGF-β-induced CTGF protein expression in AML12 and LX2 cells[1]. Kahweol (20-40 μM; 1 hour) decreases TGF-β-induced phospho-Smad2/3 expression in AML12 cells, but does not affect expression in LX2 cells[1]. Kahweol (20-40 μM) significantly decreased TGF-β-stimulated phospho-ERK and JNK expression in primary hepatocytes only[1]. kahweol (0-25 μg/ml; 6-24 hours) increased the phosphorylation of AMPK and its downstream target Acetyl-CoA carboxylase (ACC) in a time-dependent manner in 3T3-L1 cells[2]. kahweol (0-25 μg/ml) significantly affects protein expression of PPARγ, C/EBPα, FABP4, and FASN, that regulate adipocyte differentiation and lipid metabolism[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:3T3-L1 cells
-
Concentration:0, 5, 10, 25 μg/ml
-
Incubation Time:
-
Result:Reduced PPARγ, C/EBPα, FABP4, and FASN expression in a dose-dependent manner.
化学情報
-
CAS 番号 6894-43-5
-
性状 Solid
-
分子量 314.42
-
分子式 C20H26O3
-
Color Off-white to light yellow
-
SMILES
C[C@]12[C@@]3([H])[C@@]4(CC[C@]1([H])C5=C(OC=C5)C=C2)C[C@@]([C@](CO)(O)C4)([H])CC3
-
別名
Kahweol
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nat Immunol
2025 Apr 11. PMID: 40217111
溶剤 & 溶解度
DMSO : 100 mg/mL (318.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.95 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.95 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Seo HY, et al. Kahweol decreases hepatic fibrosis by inhibiting the expression of connective tissue growth factor via the transforming growth factor-beta signaling pathway. Oncotarget. 2017 Aug 1;8(50):87086-87094. [Content Brief]
[2]. Baek JH, et al. Kahweol inhibits lipid accumulation and induces Glucose-uptake through activation of AMP-activated protein kinase (AMPK). BMB Rep. 2017 Nov;50(11):566-571. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1805 mL | 15.9023 mL | 31.8046 mL | 79.5115 mL |
| 5 mM | 0.6361 mL | 3.1805 mL | 6.3609 mL | 15.9023 mL | |
| 10 mM | 0.3180 mL | 1.5902 mL | 3.1805 mL | 7.9511 mL | |
| 15 mM | 0.2120 mL | 1.0602 mL | 2.1203 mL | 5.3008 mL | |
| 20 mM | 0.1590 mL | 0.7951 mL | 1.5902 mL | 3.9756 mL | |
| 25 mM | 0.1272 mL | 0.6361 mL | 1.2722 mL | 3.1805 mL | |
| 30 mM | 0.1060 mL | 0.5301 mL | 1.0602 mL | 2.6504 mL | |
| 40 mM | 0.0795 mL | 0.3976 mL | 0.7951 mL | 1.9878 mL | |
| 50 mM | 0.0636 mL | 0.3180 mL | 0.6361 mL | 1.5902 mL | |
| 60 mM | 0.0530 mL | 0.2650 mL | 0.5301 mL | 1.3252 mL | |
| 80 mM | 0.0398 mL | 0.1988 mL | 0.3976 mL | 0.9939 mL | |
| 100 mM | 0.0318 mL | 0.1590 mL | 0.3180 mL | 0.7951 mL |
Kahweol 関連分類
HY-N6258 関連分類
Powered by Bioz